Table 2.
Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Normal range | |
---|---|---|---|---|---|---|
Complex I | 17 | 29 | 4 | 38 | 42 | 82–118 |
Complex II | 119 | 99 | 170 | 154 | 200 | 89–120 |
Complex III | 67 | 97 | 22 | 36 | 30 | 68–136 |
Complex IV | 73 | 103 | 36 | 20 | 63 | 63–123 |
Citrate synthase | 126 | 292 | 297 | 303 | 254 | 93–111 |
mtDNA/nDNA | 61 | 53 | 6 | 130 | 7 | 66–146 |
Enzyme defect | I | I | I, III, IV | I, III, IV | I, III, IV |
Enzyme activities are expressed as % of control mean relative to protein. Complex I is NADH-Coenzyme Q1 oxidoreductase; Complex II is Succinate-Coenzyme Q1 oxidoreductase; Complex III is decylbenzylquinol-cytochrome c oxidoreductase; Complex IV is cytochrome c oxidase. mtDNA/nDNA is the ratio of mitochondrial DNA relative to nuclear DNA expressed as % of control mean. ‘Normal Range’ was determined on at least six tissue samples obtained from children lacking evidence of respiratory chain disease. Methods for enzyme and DNA analyses were as described previously (Dimmock et al. 2008; Tzoulis et al. 2006)